# A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects

> **NCT05403866** · PHASE2 · COMPLETED · sponsor: **Lumosa Therapeutics Co., Ltd.** · enrollment: 89 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** LT3001 Drug Product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05403866
- **Lead sponsor:** Lumosa Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-17
- **Primary completion:** 2025-05-23
- **Final completion:** 2025-05-23
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05403866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05403866, "A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05403866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*